Back to Journals » Cancer Management and Research » Volume 12

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma

Authors Rathi N, Maughan BL, Agarwal N, Swami U

Received 16 January 2020

Accepted for publication 10 April 2020

Published 20 May 2020 Volume 2020:12 Pages 3741—3749

DOI https://doi.org/10.2147/CMAR.S202973

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Eileen O'Reilly


Nityam Rathi, Benjamin L Maughan, Neeraj Agarwal, Umang Swami

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

Correspondence: Neeraj Agarwal
Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Email neeraj.agarwal@hci.utah.edu
Umang Swami
Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Email umang.swami@hci.utah.edu

Abstract: Cabozantinib is an oral, tyrosine-kinase inhibitor with potent activity against VEGFR2 and MET, along with multiple other tyrosine kinases involved in cancer development and progression. Herein, we will focus on preclinical and clinical studies leading to the approval of cabozantinib in advanced renal cell carcinoma and hepatocellular carcinoma. Covered studies include NCT01100619, CABOSUN, METEOR, NCT00940225 and the CELESTIAL trial. Finally, we review future directions of cabozantinib development by highlighting some ongoing clinical trials.

Keywords: cabozantinib, renal cell carcinoma, hepatocellular carcinoma, kidney cancer, liver cancer, cabozantinib resistance mechanism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]